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Supplementary Figure 1.  Structures for additional compounds used in the X-ray 
crystallographic structural investigations. 
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Supplementary Figure 2.  1H (top), 13C{1H} (middle) and 31P{1H} (bottom) NMR 
spectra (D2O) of RuPEGOx. 
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Supplementary Figure 3.  1H (top), 13C{1H} (middle) and 31P{1H} (bottom) NMR 
spectra (DMSO-d6) of RuPEGCl4. 
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Supplementary Figure 4.  1H (top), 13C{1H} (middle) and 31P{1H} (bottom) NMR 
spectra (D2O) of RuC10Ox. 
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Supplementary Figure 5.  1H (top), 13C{1H} (middle) and 31P{1H} (bottom) NMR 
spectra (DMSO-d6) of RuC10Cl4. 
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Supplementary Figure 6.  Experimental electron density corresponding to the adduct 
in the X-ray crystal structure of RR-treated NCP, in stereo view.  An FO−FC omit 
electron density map (green; contoured at 2σ; RR atoms omitted from the model) and 
an anomalous difference electron density map (magenta; contoured at 4σ; indicating 
the locations of the ruthenium cations, teal spheres) are superimposed onto the refined 
model.  The RU1 and RU2 sites are at the left and right, respectively.  Further details 
can be found in Fig. 2. 
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Supplementary Figure 7.  Experimental electron density corresponding to the adduct 
in the X-ray crystal structure of C2-treated NCP, in stereo view.  An FO−FC omit 
electron density map (green; contoured at 2σ; C2 atoms omitted from the model) and 
an anomalous difference electron density map (magenta; contoured at 4σ; indicating 
the locations of the ruthenium cations, teal spheres) are superimposed onto the refined 
model.  The RU1 and RU2 sites are at the left and right, respectively.  Further details 
can be found in Fig. 2d. 
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Supplementary Figure 8.  Experimental electron density corresponding to the adducts 
in the X-ray crystal structures of SS-treated (a) and RS-treated (b) NCP.  An FO−FC 
omit electron density map (green; contoured at 2σ (a) and 3σ (b); SS/RS atoms omitted 
from the model) and an anomalous difference electron density map (magenta; 
contoured at 4σ (a) and 3σ (b); indicating the locations of the ruthenium cations, teal 
spheres) are superimposed onto the refined model.   
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Supplementary Figure 9.  Statistical analysis for the cell cycle data (Fig. 4; treatment 
with binuclear agent or RAPTA-C [RAPTA] and untreated control).  P-values for 
Fisher distances (bold values signify statistically significant differences) and the 
Mahalanobis distances are given.  
 
 
 
 
 
 
 
 
C10 C2 PEG RAPTA RR Untreated
C10 1.0000 0.0898 0.0921 < 0.0001 0.5402 0.5615
C2 0.0898 1.0000 0.6489 < 0.0001 0.0556 0.3013
PEG 0.0921 0.6489 1.0000 < 0.0001 0.0274 0.1792
RAPTA < 0.0001 < 0.0001 < 0.0001 1.0000 < 0.0001 < 0.0001
RR 0.5402 0.0556 0.0274 < 0.0001 1.0000 0.7943
Untreated 0.5615 0.3013 0.1792 < 0.0001 0.7943 1.0000
C10 C2 PEG RAPTA RR Untreated
C10 0.00 2.56 2.54 150.08 0.79 0.75
C2 2.56 0.00 0.59 178.46 3.05 1.37
PEG 2.54 0.59 0.00 189.04 3.79 1.88
RAPTA 150.08 178.46 189.04 0.00 142.46 156.15
RR 0.79 3.05 3.79 142.46 0.00 0.37
Untreated 0.75 1.37 1.88 156.15 0.37 0.00
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Supplementary Figure 10.  Western blot analysis for DNA damage response markers.  
Cellular samples correspond to untreated (unt) or treated with either cisplatin (cisPt), 
RAPTA-C (RAP), C10 or RR.  Molecular weight protein markers are designated by 
“m”.  An empty lane between the ‘m’ and ‘unt’ lanes was removed for the γ-H2AX blot.  
Full blots are shown in Supplementary Fig. 11. 
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Supplementary Figure 11.  Western blot analysis for DNA damage response markers.  
Uncropped scans corresponding to blots in Supplementary Fig.10. 
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Supplementary Figure 12.  Agarose gel analysis of nucleosome array reconstitutions.  
Numbers indicate the molar stoichiometry of histone octamer (HO) to nucleosome 
(NUC).  At the left are 250–10,000 bp DNA marker (m) and nucleosome core particle 
(NCP) for reference.  Note that saturation of the array DNA with histone octamer is 
achieved around a HO:NUC stoichiometry of 1.0, above which point the lower 
octamer-binding-affinity competitor DNA (84 bp DNA; present to prevent 
oversaturation of the array DNA) begins to heavily accumulate histone proteins 
(histone-DNA complexes). 
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Supplementary Figure 13.  Electron microscopy of negatively stained drug- and 
binuclear-treated nucleosome array.  Samples are cisplatin-, RAPTA-C (RAPTA)- and 
RR-treated (2 images) array, all in the absence of divalent metal.  The black scale bar 
inset corresponds to 100 nm. 
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Supplementary Figure 14.  Histone protein cross-linking analysis of NCP treated with 
RAPTA-C (RAP) or binuclear agent.  (a) SDS-PAGE analysis shows multiple types of 
multimeric histone protein species arising from compound treatment.  The cross-linked 
histones are categorized into two groupings (1, 2).  Similar types of species in group 1 
apparently occur for both RAPTA-C and binuclear treatments, although these are more 
prominent for the binuclears, which also display a third or additional species not seen 
for the mononuclear RAPTA drug.  On the other hand, species in group 2 are only 
found to occur for the binuclear treatments.  (b) Western blot analysis of binuclear-
 15 
treated NCP, coinciding with detection of H2A (left) or H2B (right).  The analysis 
indicates the presence of both H2A and H2B within the group 1 species, whereas only 
H2A is clearly evident in group 2.  Consistent with the enrichment of H2A in the cross-
linked species, note the heavy depletion of the monomeric form of H2A in the 
binuclear-treated samples (a).  (a,b) “NCP” and “m” designate untreated NCP control 
and molecular weight protein marker, respectively.   
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Supplementary Figure 15.  Synthetic route utilized to produce the binuclear 
compounds. 
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Supplementary Table 1.  Data collection and refinement statistics for NCP treated 
with RR, SS, RS or C2 
 
  RR    SS    RS    C2 
[Binuclear] (mM) 1 1 2 1 
Duration (h) 19 43 43 16 
Histones H. sapiens H. sapiens H. sapiens X. laevis 
     
Data collection*     
Space group P212121 P212121 P212121 P212121 
Cell dimensions       
    a (Å) 108.19 107.76 107.21 106.84 
    b (Å) 109.40 109.56 109.67 109.73 
    c (Å) 174.82 175.22 182.04 182.53 
Resolution (Å) 2.60–58.3  
(2.60–2.74) 
2.87–70.4  
(2.87–3.03) 
2.82–70.7  
(2.82–2.97) 
2.63–48.8  
(2.63–2.77) 
Rmerge (%) 5.0 (50.5) 5.5 (49.8) 6.2 (50.2) 2.8 (47.1) 
I / σI 15.0 (2.5) 15.6 (2.9) 13.3 (2.4) 31.8 (1.8) 
Completeness (%) 99.9 (99.6) 99.8 (99.1) 99.9 (99.6) 94.5 (71.6) 
Redundancy 5.8 (5.4) 5.7 (5.3) 5.8 (5.1) 5.3 (2.4) 
     
Refinement     
Resolution (Å) 2.60–58.3 2.87–70.4 2.82–70.7 2.63–47.2 
No. reflections 63,050 47,071 51,315 57,584 
Rwork / Rfree (%) 23.5 / 27.0 22.7 / 26.6 22.8 / 26.4 20.8 / 25.4 
No. atoms 12,099 12,099 12,099 12,111 
    Protein 6,094 6,094 6,094 6,086 
    DNA 5,939 5,939 5,939 5,939 
    Solvent 6 6 6 38 
    Adduct 60 60 60 48 
B-factors (Å2) 111 117 103 95 
    Protein 80 84 74 67 
    DNA 142 150 133 124 
    Solvent 147 153 127 75 
    Adduct 161 173 192 175 
R.m.s. deviations     
    Bond lengths (Å) 0.009 0.008 0.006 0.009 
    Bond angles (°) 1.45 1.41 1.20 1.45 
 
Single crystal data. 
Values in parentheses are for the highest-resolution shell. 
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Supplementary Table 2.  Data collection statistics for NCP treated with PEG, C10, 
PEGOx or C10Ox (chloride ligands substituted with oxalate) 
 
 PEG    C10  PEGOx  C10Ox 
[Binuclear] (mM) 1 2 2 2 
Duration (h) 44 39 66 66 
Histones X. laevis X. laevis X. laevis X. laevis 
     
Data collection*     
Space group P212121 P212121 P212121 P212121 
Cell dimensions       
    a (Å) 107.10 107.40 106.79 106.90 
    b (Å) 109.89 110.15 109.79 109.90 
    c (Å) 182.62 181.51 182.40 182.71 
Resolution (Å) 2.83–48.9  
(2.83–2.99) 
3.70–94.1  
(3.70–3.90) 
2.60–48.8  
(2.60–2.74) 
2.60–48.9  
(2.60–2.74) 
Rmerge (%) 2.6 (48.8) 4.2 (49.7) 3.5 (46.6) 2.6 (35.7) 
I / σI 30.6 (1.4) 13.4 (2.0) 24.2 (1.5) 37.6 (3.0) 
Completeness (%) 98.0 (88.7) 99.7 (98.3) 97.9 (89.0) 89.1 (51.4) 
Redundancy 5.0 (2.0) 5.2 (3.2) 5.1 (2.2) 5.6 (3.7) 
 
Single crystal data.  Values in parentheses are for the highest-resolution shell. 
 
 
 
Supplementary Table 3.  Data collection statistics for NCP treated with C2Ox, SSOx 
or RSOx (chloride ligands substituted with oxalate) 
 
  C2Ox  SSOx  RSOx 
[Binuclear] (mM) 2 1 2 
Duration (h) 66 23 67 
Histones X. laevis X. laevis X. laevis 
    
Data collection*    
Space group P212121 P212121 P212121 
Cell dimensions      
    a (Å) 106.94 106.80 106.89 
    b (Å) 109.82 109.81 109.81 
    c (Å) 182.73 182.51 182.59 
Resolution (Å) 2.60–48.9  
(2.60–2.74) 
2.59–48.8  
(2.59–2.73) 
2.60–48.8  
(2.60–2.74) 
Rmerge (%) 2.8 (43.8) 3.6 (48.5) 3.0 (30.3) 
I / σI 35.3 (2.4) 26.4 (1.9) 29.2 (1.8) 
Completeness (%) 96.6 (83.2) 97.7 (85.0) 95.5 (76.4) 
Redundancy 5.7 (3.6) 5.5 (3.0) 5.1 (1.9) 
 
Single crystal data.  Values in parentheses are for the highest-resolution shell. 
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Supplementary Table 4.  Binuclear binding sites in crystals of the NCP 
 
Agent Treatment (mM, h) Resolution 
(Å) 
Anomalous Peak (σ) 
Agent Conc. Duration RU1 RU2 H2A E91 
C2 1 16 2.65 8.5 6.2  
 1 38 2.88 7.9 8.3  
 2 16 2.83 6.9 6.9  
 2 38 3.47 7.4 7.0  
C10 2 16 2.77 4.6   
 2 39 3.70 6.7 3.2  
PEG 1 22 2.75 6.6 3.9  
 1 44 2.83 9.3 5.7  
 1 67 3.55 6.3 6.6  
 2 15 2.81 5.7   
 2 39 3.30 8.4 5.9  
RR 1 19 2.60 11.5 5.9  
 1 42 3.15 6.4 3.0  
SS 1 19 2.50 3.5 3.4  
 1 43 2.87 8.9 6.4  
RS 1 19 2.28 4.9   
 1 43 2.82 6.8 3.4 3.7 
 2 17 2.45 9.8   
C2Ox 1 22 2.00    
 1 44 2.60    
 2 40 2.65    
 2 66 2.60    
C10Ox 2 66 2.60    
PEGOx 1 22 2.60    
 2 66 2.60    
SSOx 1 23 2.55    
 1 44 3.00    
 2 66 2.65    
RSOx 2 41 2.60    
 2 67 2.65    
 
Peak heights from anomalous difference electron density maps ( ≥ 3σ) 
 
